logo
From Local to Landmark: Scientologists Dedicate the Historical Site of the First Dianetics Foundation

From Local to Landmark: Scientologists Dedicate the Historical Site of the First Dianetics Foundation

ELIZABETH, N.J., June 5, 2025 /PRNewswire/ — The location where Dianetics author and Scientology Founder L. Ron Hubbard established the first Foundation 75 years ago reopens to the world, restored and dedicated as a historical Landmark Site.
Nestled in a quiet part of Elizabeth, New Jersey, is an unassuming, three-story building—a structure that once unquestionably became the nexus of a global awakening.
Just 15 miles from New York City, this rejuvenated Colonial-Revival setting at 42 Aberdeen Road now joins the distinguished ranks of L. Ron Hubbard (LRH) Landmark Sites around the world.
During a spring afternoon celebration attended by Scientologists, community leaders and restoration specialists, guests weren't just honoring a historic moment. In fact, they were able to take the very first steps inside the exact rooms where Mr. Hubbard had personally taught the first Dianetics auditors, delivered the first Dianetics lectures and set in motion the first Dianetics Research Foundation.
'To be here, at this historic site on L. Ron Hubbard's path of discovery, is an honor and in a class of its own,' one guest said.
Now completely restored to its 1950 appearance, 42 Aberdeen Road is more than a building, it is the precise cornerstone where the world first turned a page and a revolution of the human mind all began.
With the May 9, 1950 publication of Dianetics: The Modern Science of Mental Health, what unfolded within these walls was nothing short of explosive—as the book began its unprecedented run of 28 weeks on the New York Times bestseller list. Almost overnight, crowds from across America began arriving without invitation, eager to meet and learn in person from the author of what was rapidly becoming the most popular book ever written on the human mind.
This site of universal influence now stands as it once did—complete with original furniture, vintage crystal doorknobs and refinished wood floors with mahogany Celtic pattern inlays. All have been restored to their glorious past, including the desk where Mr. Hubbard once wrote and the fireplace before which students gathered.
The Remington typewriter and SoundScriber dictation recorders Mr. Hubbard worked with are also on display—even his prized Ford Deluxe 'Woody' Wagon is parked outside.
Officiating the ceremony was the Church of Scientology Preservationist who oversaw the meticulous restoration. 'This site became the epicenter of a movement—one that grew from Dianetics, the first workable science of the mind, into the Scientology religion, with Churches and Missions spanning the globe,' he said. 'And for the first time, beginning today, you will be able to walk inside and stand right where it all began!'
Fittingly, and just days before the 75th Anniversary of the publication of Dianetics, dignitaries honoring the site's Grand Opening spoke of the impact of L. Ron Hubbard, both locally and globally.
The day's first guest speaker, Ms. Jennifer Costa, President and CEO of the Greater Elizabeth Chamber of Commerce, welcomed the opening as a milestone for the city. 'Here in Elizabeth, we pride ourselves on a theme that we think says everything: 'It all starts here.' And that is so very true. Elizabeth is a city of many firsts—from the first capital of the state of New Jersey to the home of our first governor and even the first submarine. Well, today we stand here in front of this breathtaking site, another first that claims Elizabeth with pride as the very place where the first Dianetics Foundation was born. We can't wait to welcome all of you to this landmark that belongs to all of us—because this is where your history and our history meet—right here at 42 Aberdeen Road.'
Mr. Thomas B. Connolly, who served as historical architect on the project, emphasized the importance of preserving the site's original character. 'Working with your team to restore this landmark was a dream. Your commitment to quality and authenticity was evident from day one and your goal was clear: to return the site to exactly how it was when Mr. Hubbard was here. As just a single example, when we peeled back the white aluminum siding that had been on the façade for decades, we uncovered a century-old surprise: the original cedar shingles, right where they had been since 1910.' Mr. Connolly added, 'And that's only one of the countless details that brought this heritage site back to life, transforming it into what you see today: the gem of the block!'
Dr. Apostle Lemmew Samuel, Founder of an Evangelical Assembly in New York City, has spent a lifetime in religious service—and spoke to the spiritual power of the Landmark Site. 'Just like those first readers who drove here back in 1950 to learn from Mr. L. Ron Hubbard himself, I now find myself on the same doorstep, drawn by the same truth from the pages of Dianetics,' Dr. Samuel said. 'I'm just getting started with Dianetics. But I know I have in my hands a way to help the people I serve—couples in crisis, youth searching for direction, anyone trying to hold their life together. I can help them find their way out of the darkness of the mind and into the light!'
Dr. Monica Sanchez, a United Nations Cultural Ambassador and Humanitarian, spoke not just of the legacy of this storied location, but of the enduring imprint L. Ron Hubbard left on Mankind. 'Sometimes we think we know the way, until life gives you a detour—one without signs. But Mr. Hubbard's work says: Here's another road. Here's the best road. That's why I call L. Ron Hubbard a GPS for humanity,' she said to the crowd. 'If I had been here on Aberdeen Road back in 1950, I would have told him: 'Take me as your student!' I would have felt very privileged just to learn by his side. But, thanks to everything he left behind and your incredible work to preserve it, we can all be his students.'
Captain Steve Nagiewicz, Executive Director Emeritus of the world-famous Explorers Club—where Mr. Hubbard was an exalted member and carried three official expedition flags—praised LRH's work as nothing short of bold discovery. 'Mr. Hubbard explored the oceans, he crossed continents, he set a course for distant stars. But his final frontier was the most uncharted territory of all: conducting a journey inside the human mind,' he said. 'Exploring the unknown, living on the edge, going where no one has gone before … it requires a rock-solid state of mind, leaving no margin for error.' Mr. Nagiewicz added, 'It's my hope that this day and this site will always remind us to push farther, reach deeper, keep exploring. And as future explorers venture to the stars, no doubt L. Ron Hubbard will be with them in spirit!'
Historic 42 Aberdeen Road has a sister in Bay Head, New Jersey, 50 miles away, where LRH wrote Dianetics. Mr. Hubbard worked in both locations during the same time period, in Bay Head for part of the year and Elizabeth for the other. The Bay Head property was previously opened as an L. Ron Hubbard Landmark Site in 2011—Mr. Hubbard's centennial year.
All told, there are seven such Landmark Sites now open on three continents around the world, including L. Ron Hubbard's heritage site at the base of Camelback Mountain in Phoenix, Arizona—known as the Birthplace of Scientology; the original Founding Church that Mr. Hubbard established in Washington, DC; the original Hubbard Communications Office on Fitzroy Street in London, England; his Linksfield Ridge estate overlooking Johannesburg, South Africa; and his headquarters at Saint Hill in East Grinstead, England.
Each Landmark Site offers a literal and visual history of the work and advances Mr. Hubbard achieved during the time he was at that particular location. Each also features a room devoted to the wider story of Mr. Hubbard's life of global exploration and research—including his revolutionary work here in Elizabeth, New Jersey. In full, the sites mark Mr. Hubbard's progressive steps to the founding of Dianetics and Scientology.
Two more Landmark Sites are set to open by this summer—one in the US and another in Southern Africa—carrying forward the legacy of places like 42 Aberdeen Road, a global tribute that echoes for generations to come.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2024 AI and IoT Technology Market Review: Insights from BCC Research
2024 AI and IoT Technology Market Review: Insights from BCC Research

Malaysian Reserve

time14 hours ago

  • Malaysian Reserve

2024 AI and IoT Technology Market Review: Insights from BCC Research

'This research review highlights the transformative impact of artificial intelligence (AI) and the Internet of Things (IoT) across industriindustries, showcasing significant market growth, technological advances, and the potential for these technologies to revolutionize operations, enhance efficiency, and drive innovation.' BOSTON, July 21, 2025 /PRNewswire/ — BCC Research announces the release of its '2024 AI & IoT Technology Research Review'. This report highlights the transformative impact of artificial intelligence (AI) and the Internet of Things (IoT) across industries, showcasing significant market growth and technological advances. Highlights: Artificial Intelligence (AI) Market: The market is projected to grow from $148.8 billion in 2023 to $1.1 trillion by the end of 2029. Compound Annual Growth Rate (CAGR): 39.7.3%. AI in Oil and Gas Market: The market is projected to grow from $2.8 billion in 2023 to $5.1 billion by the end of 2028. CAGR: 12.9%. Artificial Intelligence (AI) in Life Sciences Market: The market is projected to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029. CAGR: 27.9%. Research Coverage and Insights: This research review of 2024 AI and IoT technologies focuses on how these technologies propel digital transformation, improve operational effectiveness, and open new commercial prospects globally. Revolutionizing Industries: AI and IoT enhance automation, optimize operations, and improve efficiency across various sectors. Significant Investments: The global AI market is witnessing substantial investment as businesses recognize its potential to drive innovation, streamline processes, and create new revenue opportunities. Oil and Gas Sector: AI technologies are being integrated to optimize exploration, predictive maintenance, and resource management, helping companies improve operational efficiency and reduce costs. Life Sciences Impact: AI transforms drug discovery, patient monitoring, and healthcare analytics. In cancer research, AI-driven solutions enhance early detection, diagnosis, and personalized treatment plans, leading to better patient outcomes. Precision Medicine: Integrating AI into clinical and molecular diagnostics advances precision medicine by enabling faster and more accurate disease detection. Industrial IoT (IIoT): The IIoT market expands as businesses leverage connected devices and smart automation to optimize manufacturing, logistics, and supply chain operations. Digital Transformation: Advances in AI and IoT are driving digital transformation across industries, enabling businesses to enhance decision-making, reduce costs, and maintain a competitive edge in the global market. Research Summary: The 2024 Research Review of AI and IoT technology exemplifies the type of quantitative market data, analysis, and guidance that BCC Research has provided since 1971. This review includes highlights from the following reports published by BCC Research in 2024: IFT189C Global Artificial Intelligence (AI) Market: Investments vs Potential IFT305A AI in Oil and Gas: Global Markets and Technologies BIO255A Artificial Intelligence (AI) in Lifesciences Market BIO196B Artificial Intelligence (AI) in Cancer BIO261A AI in Clinical and Molecular Diagnostics Market IFT299A Industrial IoT (IIoT): Global Markets This Research Review provides a consolidated overview of market insights from these recent reports. The full reports referenced in this review offer additional depth on each topic, offering further context and more detailed analysis. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo:

Facioscapulohumeral Muscular Dystrophy Market Gearing Up for Outstanding Expansion Across the 7MM During the Forecast Period (2025-2034)
Facioscapulohumeral Muscular Dystrophy Market Gearing Up for Outstanding Expansion Across the 7MM During the Forecast Period (2025-2034)

Malaysian Reserve

time4 days ago

  • Malaysian Reserve

Facioscapulohumeral Muscular Dystrophy Market Gearing Up for Outstanding Expansion Across the 7MM During the Forecast Period (2025-2034)

According to DelveInsight's analysis, the market for facioscapulohumeral muscular dystrophy is anticipated to increase during the forecast period (2025–2034), owing to improved diagnosis, treatment advancements, aging demographics, increased awareness, the launch of emerging therapies, and healthcare spending globally. LAS VEGAS, July 17, 2025 /PRNewswire/ — Facioscapulohumeral muscular dystrophy (FSHD) often starts with muscle weakness in the face, shoulders, and upper arms, and gradually progresses to affect the abdominal muscles, legs, and pelvic area as the disease advances. Symptoms commonly emerge during childhood or adolescence, though they can begin at any stage of life, from infancy to old age. There is considerable variation in symptom onset and severity, even among relatives with the condition. Roughly 80% of individuals carrying the FSHD gene mutation experience symptoms, while the remaining 20% are asymptomatic, either showing no signs or only very mild symptoms that may go unnoticed until later in life. For FSHD1, children of an affected parent have a 50% likelihood of inheriting the disorder. In FSHD2, the inheritance risk depends on the genetic background of both parents, typically ranging from 25% to 50%. In 2024, the United States represented about 45% of all FSHD cases across the 7MM, with numbers projected to rise by 2034. Most US patients in 2024 scored between 7 and 10 on the RICCI scale, indicating moderate to severe levels of muscle dysfunction. Download the report to understand which factors are driving FSHD epidemiology trends @ Facioscapulohumeral Muscular Dystrophy Treatment Algorithm At present, there are no available therapies that can slow, halt, or reverse the progression of muscle weakness in facioscapulohumeral muscular dystrophy. While physical therapy can be beneficial in some cases, it is generally recommended that individuals engage in regular low-resistance and aerobic exercise. Collaborating with a physical therapist is important to create a personalized and safe exercise regimen. Some patients may benefit from surgical stabilization of the scapula to enhance their ability to raise their arms above shoulder level. Scapular fixation involves anchoring the shoulder blades to the ribs and may be performed on one or both sides. This is a complex procedure that should only be undertaken by skilled surgeons after thorough evaluation and discussion with both the surgeon and the neurologist. Additionally, medications such as NSAIDs, opioids, and antidepressants are commonly prescribed to manage FSHD-related pain. Current care practices are centered around managing complications and preserving physical function. Rehabilitation consultations are advised for individuals facing mobility or functional issues. However, there remains a significant unmet need for effective and affordable approved therapies, as existing supportive treatments are often costly and limited in efficacy. Learn more about the FSHD treatment @ New Treatment for Facioscapulohumeral Muscular Dystrophy There remains a significant unmet need in the treatment of FSHD, as current approaches primarily involve off-label therapies. Management strategies are largely aimed at alleviating symptoms and preserving physical function. Although FSHD is a progressive disorder with potentially serious long-term effects, treatment options are still limited to symptomatic care. Several investigational therapies are in development, including GYM329/RO7204239/RG6237 by Roche and Chugai Pharmaceutical, Delpacibart braxlosiran (del-brax) by Avidity Biosciences, EPI-321 by Epicrispr Biotechnologies, among others. Discover which therapies are expected to grab major FSHD market share @ Facioscapulohumeral Muscular Dystrophy Market Report GYM329 (also known as RO7204239 or RG6237) is an experimental anti-myostatin antibody aimed at enhancing skeletal muscle mass and growth. It has been specifically engineered as a 'recycling' and 'sweeping' antibody, meaning it may clear myostatin from the bloodstream more effectively than traditional antibodies. This targeted approach is expected to help address conditions marked by muscle wasting and reduced muscle strength. In November 2022, Roche began a Phase II clinical trial (NCT05548556) in patients with facioscapulohumeral muscular dystrophy, and according to the company, regulatory filing is anticipated after 2028. As per Chugai Pharmaceutical's Q1 2025 update, results from the ongoing MANOEUVRE Phase II study for FSHD are expected in 2025. With proof of concept established, Chugai plans to advance to Phase III trials, set to begin in 2026. Delpacibart braxlosiran (del-brax, formerly AOC 1020) is currently being assessed in the Phase I/II FORTITUDE trial (NCT06547216) in both adult and adolescent participants with FSHD. This study is focused on evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenously administered del-brax. In June 2025, Avidity Biosciences announced that del-brax may qualify for an accelerated approval pathway in the U.S. for FSHD treatment. The company also launched the global Phase III FORWARD trial to serve as a confirmatory study for full regulatory approval. Additionally, Avidity reported positive topline results from the dose-escalation cohorts of the FORTITUDE trial, which will be shared at the 32nd Annual FSHD Society International Research Congress. EPI-321 is an investigational, one-time gene-silencing therapy targeting abnormal DUX4 expression. Administered systemically via a validated AAV vector, EPI-321 has shown strong preclinical results, including effective suppression of DUX4 and preservation of muscle tissue. It has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA. The company is preparing to launch a global Phase I/II trial in 2025. Discover more about drugs for FSHD in development @ Facioscapulohumeral Muscular Dystrophy Clinical Trials The anticipated launch of these emerging therapies for FSHD are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the FSHD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for FSHD is expected to grow at a significant CAGR by 2034. This growth is mainly driven by increased awareness, improved diagnostic techniques, and ongoing research into genetic therapies. Rising investment from pharmaceutical companies and the emergence of targeted therapies are expanding treatment options. Regulatory support for orphan diseases is also accelerating drug development. DelveInsight's latest published market report, titled as Facioscapulohumeral Muscular Dystrophy Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the FSHD country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The FSHD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of FSHD Total Diagnosed Prevalent Cases of FSHD Type-specific Diagnosed Prevalent Cases of FSHD Gender-specific Diagnosed Prevalent Cases of FSHD Age-specific Diagnosed Prevalent Cases of FSHD Severity-specific Diagnosed Prevalent Cases of FSHD Total Treated Cases of FSHD The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM FSHD market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this FSHD market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the FSHD market. Also, stay abreast of the mitigating factors to improve your market position in the FSHD therapeutic space. Related Reports Facioscapulohumeral Muscular Dystrophy Pipeline Facioscapulohumeral Muscular Dystrophy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key FSHD companies, including Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Inc., Avidity Biosciences, Inc., among others. Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted FSHD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Duchenne Muscular Dystrophy Market Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DMD companies, including Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, Santhera Pharmaceuticals, ReveraGen BioPharma, Taiho Pharmaceutical, FibroGen, Capricor, Daiichi Sankyo, Italfarmaco, Antisense Therapeutics, Solid Biosciences, among others. Spinal Muscular Atrophy Market Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SMA companies, including Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Therapeutics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content:

PolyU launches advanced education programme, offering short courses to keep learners abreast of sci-tech developments
PolyU launches advanced education programme, offering short courses to keep learners abreast of sci-tech developments

Malaysian Reserve

time5 days ago

  • Malaysian Reserve

PolyU launches advanced education programme, offering short courses to keep learners abreast of sci-tech developments

HONG KONG, July 17, 2025 /PRNewswire/ — The Hong Kong Polytechnic University (PolyU) is committed to promoting interdisciplinary research to provide solutions to pressing societal problems. In 2022, the University established the PolyU Academy for Interdisciplinary Research (PAIR) with an aim to facilitate interdisciplinary research, transfer technologies to stakeholders, inspire innovation across disciplines, and collaborate with top institutions in the world. To raise the community's understanding of interdisciplinary collaboration and its importance in driving positive transformations within societies, the Academy launches the PAIR Advanced Education Programme, to disseminate foundational and advanced knowledge in science and technology on topics that are closely related to daily living. The first course, focusing on 'Healthy Life and Smart Living', will start this fall. This thirteen-week course, designed by PolyU experts in related disciplines, covers six applied science disciplines including: food and nutrition, sports, smart ageing, mental health, sharp vision, and Chinese medicine. Through the course, learners will understand the overall landscape of some of the pressing problems currently facing the world, as well as PolyU-led innovations that aim to tackle these issues, and technology challenges in related fields. The course does not require learners to have relevant knowledge background and is particularly suitable to individuals who wish to broaden their understanding of interdisciplinary science and know about recent developments in science and technology. The course is offered in dual mode, that is, students can choose to attend classes in-person or online, providing flexible learning options to interested learners coming from Hong Kong and abroad. Learners fulfilling attendance requirement are eligible to apply for a certificate of completion. To encourage the community's active participation in sci-tech learning, the first course is offered free of charge to eligible members of the public. The course has received enthusiastic response since its launch. Quota for physical class attendance is now full, while quota for online attendance is available on a first come, first served basis. Course enrolment will close on 31 July. For enrolment or details, please visit the programme website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store